Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Drug Development
Drug Development · The big question

Meet the AI Scientists Accelerating Medical Research

Google DeepMind and Edison Are Building the AI Scientist

GEN1 min readAI-assisted summary
Editorial illustration for Google DeepMind and Edison Are Building the AI Scientist
Editorial illustration

Summary

Tech organizations like Google DeepMind and Edison are building "AI scientists" to act as digital research partners. Recently detailed in the journal Nature, these new artificial intelligence tools aim to automate the traditional scientific process. Instead of just answering simple questions, these programs can generate original hypotheses, design lab experiments, and interpret complex data to help human researchers solve biological mysteries.

The early results are highly promising. DeepMind's tool, called Co-Scientist, has successfully identified new potential targets for treating liver scarring and predicted ways to repurpose existing drugs for a severe blood cancer known as acute myeloid leukemia. Similarly, Edison's AI, named Robin, proposed novel ways to treat a common blinding eye condition called dry age-related macular degeneration. Impressively, Robin's unique treatment ideas were later tested and validated in lab experiments using real human eye cells.

Building on this momentum, Edison has introduced an upgraded platform called Kosmos. This system is already partnering with the pharmaceutical company Incyte to sort through massive amounts of medical evidence and build predictive models for new therapies currently in the company's development pipeline.

Why it matters.

Finding and developing new medications is traditionally a slow, painstaking process. By accelerating the earliest phases of research, AI scientists could help pharmaceutical companies discover life-saving treatments much faster. If AI can connect the dots to propose a new cancer or blindness treatment, human scientists can focus their energy on testing the very best ideas, potentially saving massive amounts of time and money in early research.

Despite these exciting advances, the technology is still in its early stages. Experts caution that while AI excels at speeding up the initial discovery phase, significant bottlenecks remain. The later stages of drug development are notoriously expensive and heavily regulated, requiring strict human oversight. Building trust in these early-stage artificial intelligence systems is an ongoing challenge, meaning human scientists are still essential for navigating the complex journey of bringing a new drug to patients.

From the source

The story in numbers.

Series B funding secured by DeepMind spinout Isomorphic Labs
$2.1 billion
Documents (papers, clinical trials, patents) reasoned over by Edison's Kosmos AI
175 million
Biomedical applications validated in early testing by DeepMind's Co-Scientist
3
Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Drug Development

A $122M boost for a fast, inside-the-body approach to cell therapy

Create Medicines recently secured $122 million to advance a new class of treatments for cancer and autoimmune diseases. They specialize in CAR-T cell therapy, a treatment that engineers the immune system to fight disease. But instead of the traditional method of removing cells from a patient to alter them in a lab, Create Medicines is developing therapies that work entirely inside the body, a process known as "in vivo" treatment. To achieve this, the therapy uses tiny fat bubbles called lipid nanoparticles to deliver messenger RNA, or mRNA, into the patient. Think of mRNA as a set of biological instructions. Once delivered, these instructions directly teach the patient's existing immune cells, including T cells, natural killer cells, and myeloid cells, to reprogram themselves into disease fighters. The startup has already dosed more than 50 patients, giving it the largest clinical dataset in the in vivo field. They recently began an early-stage clinical trial for an experimental therapy designed to attack solid tumors that carry a specific protein called HER2. Alongside this cancer research, the company is testing other treatments that target proteins called CD19 and BCMA to help patients with autoimmune conditions.

BioPharma Dive1 min read
Drug Development

Supreme Court Protects Access to Common Abortion Pill

The United States Supreme Court has decided to preserve access to mifepristone, a medication used in the most common method of abortion. By rejecting recent restrictions proposed by lower courts, the Supreme Court has ensured that patients can still obtain this widely used drug while an ongoing lawsuit continues to make its way through the legal system. Under this current legal order, patients do not need an in-person visit with a doctor to get the medication. Instead, they are permitted to continue receiving mifepristone directly from pharmacies or through the mail. This ruling maintains the existing distribution methods, meaning that access is expected to remain uninterrupted at least into the following year as further legal proceedings unfold.

STAT News1 min read
Drug Development

Living Implants: Engineered Bacteria Trapped in Gel Fight Infections

What if a medical implant could sense an infection and fight it off automatically? Researchers have created exactly that with a new technology called an "implantable living material." To build it, scientists used a specialized, water-based gel known as a polyvinyl alcohol hydrogel. This material acts as a tiny, flexible fortress. It is uniquely stiff and tough, designed to hold genetically engineered bacteria safely inside for up to six months without them escaping into the surrounding tissue. Inside this protective gel, the researchers trapped a modified version of E. coli bacteria to act as molecular guards. These engineered microbes are programmed to detect chemical signals given off by Pseudomonas aeruginosa, a dangerous pathogen that frequently causes infections around artificial joints. When the trapped bacteria sense the invader, they trigger a targeted self-destruct mechanism. This intentional cellular explosion releases a powerful antibacterial protein that easily passes through the microscopic pores of the gel to kill the infection outside. The research team tested this system in mice with artificial joint infections. Over a three-day treatment period, the living implant significantly reduced the amount of infectious bacteria compared to non-therapeutic controls. By keeping the helpful microbes physically contained while allowing their medicine to flow out, the researchers have found a clever way to turn living cells into localized drug factories.

GEN2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Meet the AI Scientists Accelerating Medical Research — Daily Strand